Financings in Brief: Target Therapeutics
This article was originally published in The Gray Sheet
Executive Summary
Target Therapeutics: Extends stock repurchase program "by up to 500,000 additional shares." Target has already completed a buy back of 350,000 shares "authorized for repurchase upon initiation of the repurchase program in May 1996"...